

DAFTAR PUSTAKA

- Ahmad, S., 2010. Review Article: Pathogenesis, Immunology, and Diagnosis of Latent Mycobacterium tuberculosis Infection. ***Clinical and Developmental Immunology***.
- American Thoracic Society, 1998. Dyspnea Mechanisms, Assessment, and Management: A Consensus Statement. ***American Journal of Respiratory and Critical Care Medicine***. Vol. 159.
- Batista, A.L.B., Albuquerque, M.F.P.M., Ximenes, R.A.A., Rodrigues, L.C., 2008. Smoking Increase the Risk of Relapse After Successful Tuberculosis Treatment. ***International Journal of Epidemiology***. Vol. 37 No. 84, p. 841-851.
- Bailie, G.R., Johnson, C.A., Mason, N.A., Peter, W.L., 2004. ***MedFacts Pocket Guide of Drug Interactions***. Bone Care International and Nephrology Pharmacy Associates.
- Baxter, K., 2008. ***Stockley's Drug Interactions***. Pharmaceutical Press.
- Boekitwetan, P., 1999. Resistensi Multipel Obat Antituberkulosis. ***Jurnal Kedokteran Trisakti***. Vol. 18 No. 1, p. 41-51.
- Caminero, J.A., 2013. Chapter 9: Tuberculosis Drug: Mechanism of Action and Rationale for Use. In: Caminero, J.A. (Eds.). ***Guideline for Clinical and Operational Management of Drug-Resistant Tuberculosis***. France: International Union Against Tuberculosis and Lung Disease (The Union), pp. 111-132.
- Caminero, J.A., Sotgiu, G., Zumla, A., Migliori, G.B., 2010. Best Drug Treatment for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. ***Lancet Infect. Dis***, Vol. 10, p. 621-9.
- Chang, K.C. and Yew, W.W., 2012. Management of Difficult Multidrug-Resistant Tuberculosis and Extensively Drug-

Resistant Tuberculosis. *Asian Pacific Society of Respirioly*, Vol. 18, p. 8-21.

Chan, C.Y., Yeang, C.A., Yew, W.W., Hui, M., Cheng, A.F.B., 2001. Posantibiotic Effects of Antituberculosis Agents Alone and in Combination. *Antimicrobial Agents and Chemotherapy*. Vol. 45 No. 12, p. 3631-3634.

Chan, C.Y., Yeang, C.A., Yew, W.W., Leung, C.C., Cheng, A.F.B., 2004. In Vitro Postantibiotik Effects of Rifapentine, Isoniazid, and Moxifloxacin Againts Mycobacterium tuberculosis. *Antimicrobial Agents and Chemotherapy*. Vol. 48 No. 1, p. 340-343.

Chiang, C.Y., 2013. Chapter 3: Basic Concepts and Definitions of Drug Resistance in Tuberculosis. In: Caminero, J.A. (Eds.). *Guideline for Clinical and Operational Management of Drug-Resistant Tuberculosis*. France: International Union Against Tuberculosis and Lung Disease (The Union), pp.25-37.

72

Cook, G.M., Berney, M., Gebhard, S., Heinemann, M., Cox, R.A., Daanilchanka, O., Niederweis, M., 2013. Physiologi of Mycobacteria. *Adv. Microb. Physiol*, Vol. 55, p. 81-319.

Deck, D.H. and Winston, L.G., 2011. Chapter 47: Antimycobacterial Drugs. In: Katzung, G.G., Masters, S.B., Trevor, A.J. (Eds.). *Basic & Clinical Pharmacology*. 12th Edition. New York: The McGraw-Hill Companies, pp. 839-847.

Departemen Kesehatan Republik Indonesia, 2011. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta: Departemen Kesehatan Republik Indonesia.

Departement Health Republic of South Africa. 2014. *National Tuberculosis Management Guidelines*. Departement of Health, Republic of South Africa.

Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan, 2005. *Pharmaceutical Care Untuk Penyakit Tuberkulosis*. Jakarta:

Direktorat Bina Farmasi Komunitas dan Klinik, Direktorat Jendral Bina Kefarmasian dan Alat Kesehatan, Departemen Kesehatan Republik Indonesia.

- Forrellad, M.A., Klepp, L.I., Gioffré, A., García, J.S., Morbidoni, H.R., Santangelo, M.P., Cataldi, A.A., Bigi, F., 2013. Review: ***Virulence Factors of the Mycobacterium tuberculosis Complex***, Vol. 4 No. 1, p. 3-66.
- Gama, H., 2008. Drug Utilization Studies. ***Arquivos De Medicina***, Vol. 22 No. 2/3, p. 69-74.
- Gengenbacher, M. and Kaufmann, S.H.E., 2013. Mycobacterium tuberculosis: Success Through Dormancy. ***FEMS Microbiol. Rev.*** Vol. 16 No. 3, p. 514-532.
- Guirado, E., Schlesinger, L.S., Kaplan, G., 2013. Macrophages in Tuberculosis: Friend or Foe. ***Semin Immunopathol***, Vol. 53 No. 5, p. 563-583.
- Gumbo, T., Louie, A., Liu, W., Brown, D., Ambrose, P.G., Bhavani, S.M., Drusano, G.L., 2007. Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations. ***Antimicrobio. Agents Chemother.*** Vol. 57 No. 7, p. 2329-2336.
- Hunter, R.L., 2011. Pathology of Post Primary Tuberculosis of the Lung: An Illustrated Critical Review. ***Tuberculosis (Edinb)***, Vol, 91 No. 6, p. 497-509.
- Istantoro, Y.H. dan Setiabudi, R., 2007. Bab 40: Tuberkulostatik dan Leprostatik. In: Gunawan, S.G (Eds.). ***Farmakologi dan Terapi***. Edisi 5. Jakarta: Balai Penerbit FKUI.
- Kaur, S., Rajagopalan, S., Kaur, N., Shafiq, N., Bhalla, A., Pandhi, P., Malhotra, S., 2014. Research Article: Drug Utilization Study in Medical Emergency Unit of a Tertiary Care Hospital in North India. ***Emergency Medecine International.***

- Kays, M.B., 2013. Chapter 65: Tuberculosis. In: Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kardjan, W.A., Williams, B.R. (Eds.). ***Applied Therapeutics The Clinical Use of Drugs***. 10th Edition. Philadelphia: Lippincott Williams & Wilkins, pp. 1534-1580.
- Kementerian Kesehatan Republik Indonesia, 2013. ***Profil Kesehatan Indonesia Tahun 2013***, Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan Republik Indonesia, 2014. ***Pedoman Nasional Pengendalian Tuberkulosis***, Jakarta: Kementerian Kesehatan Republik Indonesia Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan.
- Long, R. and Schwartzman, K., 2014. Chapter 2: Pathogenesis and Transmission of Tuberculosis. In: Menzies D. (Eds.). ***Canadian Tuberculosis Standards***. 7th Edition. Ottawa: Public Health Agency of Canada, The Lung Association, Canadian Thoracic Society, pp. 28-45.
- McEvoy, G.K., 2011. ***AHFS Drug Information***. United States of America: American Society of Health-System Pharmacist, Inc.
- Menzies, D. and Elwood, K., 2014. Chapter 5: Treatment of Tuberculosis Disease. In: Menzies D.(Eds.). ***Canadian Tuberculosis Standards***. 7th Edition. Ottawa: Public Health Agency of Canada, The Lung Association, Canadian Thoracic Society, pp. 100-126.
- Mishra, A.K., Driessen, N.N., Appelmelk, B.J., Besra, G.S., 2011. Review Article: Lipoarabinomannan and Glycoconjugates: Structure, Biogenesis and Role in Mycobacterium tuberculosis Physiology and Host-Pathogen Interaction. ***FEMS Microbiol. Rev.*** Vol. 35, p. 1126-1152.
- National Institute of Allergy and Infectious Diseases, 2012. ***First Line Treatment of Tuberculosis (TB) for Drug-Sensitive TB***. Diakses dari



<https://www.niaid.nih.gov/topics/tuberculosis/understanding/whattistb/scientificillustrations/pages/firstlineillustration.aspx>

- Pai, M., Minion, J, Wolfe, J., Behr, M., 2014. Chapter 3: Diagnosis of Active Tuberculosis and Drug Resistance. In: Menzies D. (Eds.). **Canadian Tuberculosis Standards**. 7th Edition. Ottawa: Public Health Agency of Canada, The Lung Association, Canadian Thoracic Society, pp. 46-64.
- Palomino, J.C. and Martin, A., 2014. Drug Resistance Mechanism in Mycobacterium Tuberculosis. **Antibiotics**. Vol, 3, p. 317-340.
- Peloquin, C.A., 2008. Chapter 116: Tuberculosis. In: Dipro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M.(Eds.). **Pharmacotherapy A Pathophysiologic Approach**. 7th Edition. New York: The McGraw-Hill Companies, pp. 1872-1889.
- Petri, W.A., 2006. Chapter 47: Chemotherapy of Tuberculosis, Mycobacterium aviumComplex, and Leprosy. In: Brunton, L.L. (Eds.). **Goodman & Gilman's the Pharmacological Basis of Therapeutics**. 11th Edition. New York: The McGraw-Hill Companies.
- Raviglione, M.C. and O'Brien, R.J., 2008. Chapter 158: Tuberculosis. In: Fauci, A.S., Kasper, D.L., Longo, D.L., Braunwald, E., Hauser, L., Jameson, J.L., Loscalzo, J.(Eds.). **Harrison's Principle of International Medicine**. 17th Edition. New York: The McGraw-Hill Companies, pp. 1157-1171.
- Sachdeva, P.D. and Patel, B.G., 2010. Drug Utilization Studies-Scope and Future Perspectives. **International Journal on Pharmaceutical and Biological Research**, Vol. 1 No. 1, p. 11-17.
- Shalini, S., Ravichandran, V., Mohanty, B.K., Dhanraj, S.K., Saraswanthi, R., 2010. Review Article: Drug Utilization Studies- And Overview. **International Journal of Pharmaceutical Sciences and Nanotechnology**, Vol. 3, p. 803-810.

- Tatro, D.S., 2009. ***Drug Interaction Facts***. Wolters Kluwer Health, Inc.
- TB CARE I, 2014. ***International Standards for Tuberculosis Care***. 3rd Edition. San Fransisco: TB CARE I.
- Tuberculosis Coalition for Technical Assistance, 2007. ***Handbook for Using the International Standards for Tuberculosis Care***. San Fransisco.
- Varaine and Rich, 2014. ***Tuberculosis: Practical Guide for Clinicians, Nurses, Laboratory Technicians and Medical Auxiliaries***. Paris: Medecins Sans Frontieres.
- Wochenschr, W.K., 2007. Pulmonary Tuberculosis. ***The Mid. Eur. J. Med***, Vol. 119, p. 13-14.
- World Health Organization, 2003. ***Introduction to Drug Utilization Research***. Geneva: World Health Organization.
- World Health Organization, 2010. ***Treatment of Tuberculosis Guidelines***. 4th Edition. Geneva: World Health Organization Press.

LAMPIRAN 1

F.LITB.003



**KOMITE ETIK PENELITIAN KESEHATAN
RSUD Dr. SOETOMO SURABAYA**

**KETERANGAN KELAIKAN ETIK
("ETHICAL CLEARANCE")**

43 / Panke.KKE / I / 2015

KOMITE ETIK RSUD Dr. SOETOMO SURABAYA TELAH MEMPELAJARI SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA PENELITIAN DENGAN JUDUL :

**"Studi Penggunaan Obat Anti Tuberkulosis (OAT)
Pada Pasien Tuberkulosis Paru"**

PENELITI UTAMA : Chindya Marcha Ayu

**PENELITI LAIN : 1. Samirah, S.SI., Sp.FRS., Apt
2. Tutik Kusmiati, dr., Sp.P**

UNIT / LEMBAGA / TEMPAT PENELITIAN: RSUD Dr. Soetomo Surabaya

DINYATAKAN LAIK ETIK

SURABAYA, 16 FEB 2015

KETUA

(Prof. Hari Sukanto, dr., Sp.KK (K))
NIP. 19471115 197303 1 001

